Journal Article

C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer’s disease

Angeli, Stella, Fella, Eleni, Papacharalambous, Revekka, Panayiotou, Elena, Gerasimou, Petroula, Costeas, Paul, Andreou, Savanna, Kyriakides, Theodoros, Papacostas, Savvas, Kousiappa, Ioanna

2019

Overview

According to the amyloid hypothesis of Alzheimer's disease (AD) the deposition of prefibrillar and fibrillar Aβ peptide sets off the pathogenic cascades of neuroinflammation and neurodegeneration that lead to synaptic and neuronal loss resulting in cognitive decline. Various approaches to reduce amyloid load by reducing production of the Aβ peptide or enhancing amyloid clearance by primary or secondary immunization have not proven successful in clinical trials. Interfering with the normal function of secretases and suboptimal timing of Aβ peptide removal have been put forward as possible explanations. Complement, an innate component of the immune system, has been found to modulate disease pathology and in particular neuronal loss in the AD mouse model but its mechanism of action is complex. C1Q has been shown to facilitate phagocytosis of Aβ peptide but its Ablation attenuates neuroinflammation. Experiments in AD mouse models show that inhibition of complement component C5a reduces amyloid deposition and alleviates neuroinflammation. Phagocytes including microglia, monocytes and neutrophils carry C5a receptors. Here, a widely used mouse model of AD, 5XFAD, was intermittently treated with the oral C5a receptor agonist EP67 and several neuronal and neuroinflammatory markers as well as memory function were assessed. EP67 treatment enhanced phagocytosis, resulting in a significant reduction of both fibrillar and non-fibrillar Aβ, reduced astrocytosis and preserved synaptic and neuronal markers as well as memory function. Timely and phasic recruitment of the innate immune system offers a new therapeutic avenue of treating pre-symptomatic Alzheimer disease.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Ablation / Age / Agonists / Alzheimer Disease - genetics / Alzheimer Disease - metabolism / Alzheimer's disease / Alzheimers disease / Amyloid - drug effects / Amyloid - metabolism / Amyloid beta-Peptides - metabolism / Animal models / Animals / Biology and Life Sciences / Brain - drug effects / Brain - metabolism / Clinical trials / Cognitive ability / Complement component C1q / Complement component C5a / Dementia / Deposition / Disease Models, Animal / Genetics / Gliosis / Immune clearance / Immune system / Immunization / Immunological memory / Inflammation / Innate immunity / Kinases / Laboratories / Leukocytes (neutrophilic) / Markers / Medicine / Medicine and Health Sciences / Memory / Memory - drug effects / Mice / Mice, Transgenic / Microglia / Monocytes / Mutation / Neurodegeneration / Neurodegenerative diseases / Neurology / Neurons - drug effects / Neurons - metabolism / Neurosciences / Neutrophils / Oligopeptides - pharmacology / Pathology / Peptides / Phagocytes / Phagocytosis / Phagocytosis - drug effects / Proteins / Receptors / Research and Analysis Methods / β-Amyloid